| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococcus spp. (coagulase-negative + methicillin-susceptible) |
- |
0.016 |
? － ? |
L-786,392 (Peptide)  |
303 |
| Staphylococcus spp. (coagulase-negative + methicillin-susceptible) |
- |
0.03 |
? － ? |
Imipenem |
303 |
| Staphylococcus spp. (coagulase-negative + methicillin-susceptible) |
- |
- |
191.5 － 308.5 |
Acacia aroma leaf (Ethanol extract) |
321 |
| Staphylococcus spp. (coagulase-negative + methicillin-susceptible) |
- |
- |
194.4 － 305.6 |
Acacia aroma flower (Ethanol extract) |
321 |
| Staphylococcus spp. (coagulase-negative + oxacillin-resistant) |
1 |
2 |
0.06 － 4 |
Oritavancin (LY333328) |
43 |
| Staphylococcus spp. (coagulase-negative + oxacillin-resistant) |
>1 |
>16 |
≤0.008 － >16 |
Imipenem |
493 |
| Staphylococcus spp. (coagulase-negative + oxacillin-resistant) |
2 |
2 |
0.5 － 4 |
Vancomycin (Vancocyn, Lyphocin) |
43 |
| Staphylococcus spp. (coagulase-negative + oxacillin-resistant) |
2 |
64 |
0.06 － 64 |
Teicoplanin (Targocid) |
43 |
| Staphylococcus spp. (coagulase-negative + oxacillin-resistant) |
>8 |
>16 |
0.06 － >16 |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
493 |
| Staphylococcus spp. (coagulase-negative + oxacillin-resistant) |
>8 |
>16 |
0.06 － >16 |
Ertapenem (Invanz) |
493 |
| Staphylococcus spp. (coagulase-negative + oxacillin-resistant) |
>32 |
>32 |
0.12 － >32 |
Amoxicillin-clavulanate |
493 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
0.016 |
0.06 |
≤0.008 － 1 |
Imipenem |
493 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
0.12 |
0.25 |
≤0.06 － >8 |
Clindamycin (Cleocin) |
412 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
0.12 |
0.5 |
0.03 － 4 |
Ertapenem (Invanz) |
493 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
0.12 |
2 |
≤0.03 － >4 |
Gatifloxacin (Tequin) |
412 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
0.25 |
0.5 |
0.03 － 2 |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
493 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
>0.25 |
>2 |
0.06 － >2 |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
412 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
0.25 |
4 |
≤0.03 － 32 |
Amoxicillin-clavulanate |
493 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
≤0.5 |
≤0.5 |
≤0.5 － >8 |
Imipenem |
412 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
0.5 |
1 |
≤0.5 － 8 |
Zosyn |
412 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
0.5 |
2 |
≤0.01 － 2 |
Oritavancin (LY333328) |
43 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
0.5 |
2 |
0.03 － 4 |
Teicoplanin (Targocid) |
43 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
0.5 |
2 |
≤0.12 － 8 |
Cefepime (Maxipime) |
412 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
>0.5 |
>2 |
≤0.5 － >2 |
Co-trimoxazole (Trimethoprim-sulfamethoxazole, TMP-SMX) |
412 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
1 |
2 |
≤0.12 － 4 |
Vancomycin (Vancocyn, Lyphocin) |
412 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
1 |
2 |
0.25 － 2 |
Vancomycin (Vancocyn, Lyphocin) |
43 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
2 |
4 |
≤0.25 － >32 |
Ceftriaxone (Rocephin) |
412 |
| Staphylococcus spp. (coagulase-negative + oxacillin-susceptible) |
4 |
8 |
0.25 － >16 |
Ceftazidime (Ceptaz, Fortaz, Tanicef) |
412 |